DMT 200

Drug Profile

DMT 200

Alternative Names: DMT 210; DMT 220; DMT200; SIG 990

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Signum Biosciences
  • Developer Dermata Therapeutics; Signum Biosciences
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules; Terpenes
  • Mechanism of Action G protein-coupled receptor antagonists; GTP-binding protein modulators; Interleukin 4 inhibitors; Interleukin 6 inhibitors; Interleukin-17 inhibitors; Toll like receptor 2 antagonists; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Rosacea
  • Preclinical Acne vulgaris

Most Recent Events

  • 28 Feb 2017 Early research in Rosacea in USA (Ophthalmic) (Dermata Therapeutics pipeline, February 2017)
  • 28 Feb 2017 Preclinical trials in Acne vulgaris in USA (Topical) (Dermata Therapeutics pipeline, February 2017)
  • 01 Jan 2017 Phase-II clinical trials in Rosacea in USA (Topical) (NCT03003104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top